Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of saxagliptin + dapagliflozin add-on to metformin versus saxagliptin or dapagliflozin add-on to metformin in type 2 diabetes
2012-000679-18Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Saxagliptin + dapagliflozin + metformin, Placebo + saxagliptin + metformin and Placebo + dapagliflozin + metformin (3 arms). Primary endpoint: Mean change from baseline in HbA1c at Week 24. Started Oct 2012; status: completed.
02
Drugs
saxagliptindapagliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-000679-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000679-18.